Boceprevir

SKU: orb1302390

Description

Boceprevir is a potent and selective oral inhibitor of the HCV NS3 protease, exhibiting a Ki of 14 nM in enzymatic assays and an EC90 of 350 nM in cellular replicon systems. It has been utilized in both in vitro and in vivo research to study hepatitis C virus replication and protease inhibitor mechanisms.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Images & Validation

−

Key Properties

−

CAS Number	394730-60-0
MW	519.68
Purity	99.16% (May vary between batches)
Formula	C₂₇H₄₅N₅O₅
SMILES	C(NC(CC1CCC1)C(C(N)=O)=O)(=O)[C@@H]2[C@@]3([C@@](C3(C)C)(CN2C([C@@H](NC(NC(C)(C)C)=O)C(C)(C)C)=O)[H])[H]
Target	HCV Protease,SARS-CoV
Solubility	DMSO:91 mg/mL (175.11 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.85 mM)

Bioactivity

−

Target IC50	HCV NS3 protease:14nM(Ki）
In Vivo	Boceprevir is a chemical compound designed as an HCV Protease Inhibitor for treating Hepatitis C Virus Infection. Its pharmacokinetic properties have been assessed across different animal species. Following oral administration, Boceprevir exhibits moderate absorption in rats (10 mg/kg), dogs (3 mg/kg), and monkeys (3 mg/kg), with absorption being relatively quicker in dogs compared to slower rates in mice (10 mg/kg), rats, and monkeys, as indicated by mean absorption times (MAT) of 0.5 to 1.4 hours. The compound demonstrates effective area under the curve (AUC) values in dogs and rats, moderate values in mice, and lower values in monkeys. Its absolute oral bioavailability ranges from modest (26-34%) in mice, rats, and dogs, to low (4%) in monkeys. Additionally, Boceprevir, at a dosage of 100 mg/kg orally, effectively inhibits HCV NS3/4A protease activity in triple-transgenic mice. Read more...
In Vitro	In the HCV NS3 protease continuous assay, Boceprevir (SCH 503034) has a potency of 14 nM (Ki) average over a large number of runs. In the 72-h bicistronic subgenomic cell-based replicon assay in HuH-7 cells, the EC50 and EC90 values are determined to be 0.20 μM and 0.35 μM, respectively. Boceprevir is also found to be a very weak inhibitor of HNE (Ki=26 μM) representing a selectivity of 2200. Read more...

Storage & Handling

−

Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

EBP520, EBP-520, EBP 520, Boceprevir, inhibit, Inhibitor, HCVProtease, HCV Protease, HCV NS3 protease, HCV, Hepatitis C virus, SCH503034, SCH-503034, SCH 503034, SARS-CoV, SARSCoV, SARS coronavirus

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID

10324367 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Boceprevir (orb1302390)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Purity:	>98% (HPLC)
CAS Number:	394730-60-0
MW:	519.6767
Formula:	C₂₇H₄₅N₅O₅

Boceprevir

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Boceprevir [orb1225120]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Boceprevir (orb1302390)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors